Recently, good news has come from the preparation products of Tianjin Tianyao Pharmaceuticals Co.,Ltd.. Its subsidiary company, Tianjin Jin Yao Pharmaceutical Co., Ltd, received the Drug Registration Certificate for Travoprost Eye Drops approved and issued by National Medical Products Administration; At the same time, it was announced that Hubei Jin Yao, another subsidiary, received the Notice of Approval for Drug Supplementary Application for citicoline sodium injection and piracetam injection approved and issued by National Medical Products Administration, which approved the above two drugs to pass the consistency evaluation of generic drug quality and efficacy.

According to the announcement, Travoprost Eye Drops is used to reduce the elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Citicoline sodium injection is used for acute craniocerebral trauma and consciousness disorder after brain surgery; And piracetam injection is used for memory and thinking impairment caused by brain trauma and cerebrovascular diseases. Among them, citicoline sodium injection and piracetam injection belong to Class B varieties of the National Insurance Medicine List in 2022.

The above three preparations have broad market prospects, and realized domestic market scale over 100 million. According to the national enlarged hospital data of MENET (including urban public hospitals, county-level public hospitals, urban community hospitals and township hospitals), the domestic sales of Travoprost Eye Drops in 2021 and 2022 were 90.68 million yuan and 106.28 million yuan respectively; The domestic sales of citicoline sodium injection were 534.3 million yuan and 321.73 million yuan respectively; The domestic sales of piracetam injection were 646 million yuan and 530.19 million yuan respectively.    

Tianjin Tianyao Pharmaceuticals Co.,Ltd. is a leading enterprise in the whole industrial chain of "APIs plus preparations" with steroid hormones and amino acids as the core, which mainly creates its profits from preparation business segment. In recent years, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has continuously enriched its preparation varieties and enhanced the competitive strength of its preparation products through the research and development of new drugs and actively promoting consistency evaluation, which has a positive impact on the company's performance. Up to now, the company has more than 20 products passed the consistency evaluation one after another; more than ten products have obtained the Drug Registration Certificate; A number of key preparations have achieved an annual sales income of over 100 million.